Novo Nordisk has emerged as a formidable force, showcasing an impressive ascent of 68.9% over the past year alone. This meteoric rise, translating to a market capitalization of $430 billion, underscores the company's prowess in delivering substantial returns, boasting a staggering 7,800% growth trajectory for shareholders since March 2004.
The recent green light from the U.S. Food and Drug Administration (FDA) heralds a pivotal milestone for Novo Nordisk, as it secures additional approval for its groundbreaking weight-loss medication, Wegovy. Elevating its utility, Wegovy now addresses cardiovascular risk reduction in overweight individuals, heralding a newfound revenue avenue for the pharmaceutical juggernaut.
The bottom line is Novo Nordisk’s sales are expected to rise by 23.5% to $41.77 billion in 2024, and by 18.2% to $49.4 billion in 2025, according to experts. Adjusted earnings are forecast to expand to ~$3 per share in 2024, with continued growth to $3.97 per share in 2025.
Market Cap: 430.86 billion USD
Current Stock Price: $126.99
52-week range: High - $138.28 & Low - $75
Earnings Per Share: $0.71 (72% increase YoY)
Dividend Yield: 0.40 % annual, $0.13 quarterly